<DOC>
	<DOCNO>NCT00363116</DOCNO>
	<brief_summary>The purpose study determine safety efficacy two dosing regimen daclizumab simultaneous kidney/pancreas transplant recipient .</brief_summary>
	<brief_title>A Trial Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus , Mycophenolate Mofetil , &amp; Steroids Prevention Acute Allograft Rejection Simultaneous Kidney/Pancreas Transplant Recipients</brief_title>
	<detailed_description>The purpose study determine safety efficacy two dosing regimen daclizumab adjunctive immunosuppressive agent simultaneous kidney/pancreas transplant recipient receive tacrolimus , mycophenolate mofetil , steroid primary maintenance immunosuppression .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Simultaneous kidney/pancreas transplant recipient Insulin dependent Type 1 2 diabetes pretransplant Recipient age 1865 year Donor age 565 year Women must negative serum pregnancy test practice birth control study duration Negative Tcell crossmatch Parent ( guardian ) able understand consent form give write informed consent Prior treatment daclizumab Known sensitivity contraindication tacrolimus , MMF , steroids Patient significant active infection Patients positive lymphocytotoxic crossmatch use donor lymphocyte recipient serum Patients whose life expectancy severely limited disease renal disease Ongoing substance abuse , drug alcohol Major ongoing psychiatric illness recent history noncompliance Insufficient cardiovascular reserve Malignancy within last 5 year , exclude nonmelanoma skin cancer Serologic evidence infection HIV Hepatitis B surface antigen positive Investigational drug within 30 day prior transplant surgery AntiT cell therapy within 30 day prior transplant surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>Pancreas transplant</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Steroids</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Acute allograft rejection</keyword>
</DOC>